Treatment | Indications | Typical regimen | Mechanism of action | Evidence |
Antibiotics | - Acute exacerbations (all patients)
| - Amoxicillin-clavulanate for 14 days for mild exacerbations
- IV antibiotics for severe exacerbations or for patients who do not respond to a long course (4 weeks) of oral antibiotics
| - Decrease the bacterial load and interrupt the cycle of infection and inflammation
- Macrolide antibiotics (eg, azithromycin) are an alternative to amoxicillin-clavulanate and also have antiinflammatory effects
| - Antibiotics are superior to placebo to treat nonsevere exacerbations[1]; treatment response is more rapid for amoxicillin-clavulanate compared with azithromycin[2]
|
- Eradication of P. aeruginosa when first detected in sputum cultures
| - IV antipseudomonal antibiotics for 2 weeks, followed by inhaled tobramycin or colistin for 1 to 4 months
| - Pseudomonas can be eradicated when first detected but not after chronic infection is established
| - Expert consensus, based on indirect evidence from bronchiectasis in adults and early eradiation protocols in patients with cystic fibrosis[3]
|
- Chronic treatment (for selected patients with frequent exacerbations)
| - Azithromycin 30 mg/kg/week orally, divided into daily, thrice-weekly, or weekly doses (maximum 1500 mg/week)*
| | - Evidence is strongest for macrolides, which demonstrate 50% reduction in exacerbations[4]
|
Airway clearance techniques | - All children with bronchiectasis (guided by an expert physiotherapist)
| - Any of several techniques, including chest percussion, positive airway pressure, forced expirations, and exercise (choice depends on child's age and developmental stage)
| - Improves mucus clearance; may decrease cough frequency
| - RCTs in adults with stable-state bronchiectasis found that airway clearance techniques and exercise training improved exercise capacity, dyspnea, and fatigue with fewer pulmonary exacerbations[5,6]
- No RCTs for exacerbations or in children
|
Mucolytics | - Acute exacerbation (adjunctive therapy for patients with high sputum load)
| - Inhaled hypertonic saline (6 to 7%) twice daily, before airway clearance therapy (chest physiotherapy)
- Administer a bronchodilator prior to each treatment
| - Improves mucus clearance by reducing viscosity, enabling ciliary clearance and promoting cough
| - RCT in children with bronchiectasis showed higher mean improvement in predicted FEV1 when inhaled hypertonic saline was added to conventional airway clearance therapy[7]
- RCTs in adults with bronchiectasis had equivocal results for inhaled mannitol and NAC[8,9,10]; rhDNAse can be harmful
|
- Chronic treatment (for selected patients with moderate or severe daily symptoms or difficulty in expectoration)
| - Inhaled hypertonic saline or dry-powder mannitol, administered as described above
|
Bronchodilators | - Patients with coexistent asthma or bronchial hyperreactivity
| | - Improves airflow; may improve mucus clearance
| - Based on indirect evidence from management of asthma and clinical experience in children and adults with bronchiectasis and coexistent asthma[3]
|
Inhaled glucocorticoids | - Patients with coexistent asthma, airway eosinophilia, or bronchial hyperreactivity
| - Inhaled glucocorticoids, as indicated for the asthma
| - Decreases airway eosinophilic inflammation
| - Meta-analysis found insufficient evidence to support routine use in adults with bronchiectasis[11]; no RCTs in children
|
Systemic glucocorticoids | - Patients with acute asthma exacerbation
- Patients with ABPA
| - Brief course of oral glucocorticoids
- Oral glucocorticoids as indicated for treatment of ABPA
| | - No RCTs in adults or children with bronchiectasis[12]; evidence from other populations suggests that systemic steroids may increase risk of P. aeruginosa, in addition to other adverse effects of systemic steroids
|
Vaccines | - All patients with bronchiectasis
| - Ensure completion of all routine childhood vaccinations
- Annual influenza vaccine (inactivated form)¶
- Pneumococcal vaccination as recommended for high-risk patientsΔ
| - Provide immunity against influenza, pneumococcal respiratory infections, and other vaccine-preventable diseases
| - RCT in adults with bronchiectasis found that the 23-valent pneumococcal polysaccharide vaccine reduced acute pulmonary exacerbations[13]
|